FDA Approves Subcutaneous Isatuximab-irfc - Quiz - MDSpire

FDA Approves Subcutaneous Isatuximab-irfc

The approval expands subcutaneous use across newly diagnosed and previously treated multiple myeloma.

  • By

  • Kathryn Wighton

  • July 10, 2026

  • 2 min

Share

Original Source(s)

FDA Approves Subcutaneous Isatuximab-irfc

  • by Kathryn Wighton

  • July 10, 2026

Related Content

Can Belzutifan Improve Adjuvant Therapy?

The phase 3 LITESPARK-022 trial compared adjuvant pembrolizumab plus belzutifan with pembrolizumab plus placebo following resection of clear-cell renal-cell carcinoma.

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.

Side Effects: Bro Science, Actually

Creatine's ATP-buffering trick isn't just for biceps. In mice, it juices up dendritic cells' energy supply, sharpening T-cell priming and shrinking tumors on daily injections. Human DCs got the memo too, at least in a dish. Early days, but a fun plot twist for gym-bag chemistry.